NCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
Clinical Trials
9 trialsNCT06491446 2026-02-18
Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts
Antiva Biosciences
Phase 1/2 Active not recruiting
NCT04607850 2025-08-28
Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions
Barinthus Biotherapeutics
Phase 1/2 Completed
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04724980 2025-06-11
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
Precigen, Inc
Phase 1/2 Active not recruiting
NCT03610581 2025-02-04
Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix
Janssen Vaccines & Prevention B.V.
Phase 1/2 Terminated
NCT06797986 2025-01-29
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC.
Cellid Co., Ltd.
Phase 1/2 Not yet recruiting
NCT02535104 2018-06-06
Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)
Tamir Biotechnology, Inc.
Phase 1/2 Completed
NCT01532102 2018-05-30
Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
Vaxart
Phase 1/2 Completed